Advertisement


Stephen M. Ansell, MD, PhD, on Precision Immunotherapy for Refractory Hodgkin Lymphoma

2016 Pan Pacific Lymphoma Conference

Advertisement

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.



Related Videos

Julie M. Vose, MD, MBA, on Basket Trials

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses this evolution of clinical trials, and using genomic methods to direct therapy.

Multiple Myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, on Managing Multiple Myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, of the Cleveland Clinic, discusses working with patients with multiple myeloma to minimize the toxicity of their treatment and improve their outco...

Lymphoma

John G. Gribben, MD, DSc, on Follicular Lymphoma: Still a Role for Transplant?

John G. Gribben, MD, DSc, of Barts Cancer Institute, discusses the pros and cons of both autologous and allogeneic stem cell transplantation in follicular lymphoma, and the challenges...

Multiple Myeloma

S. Vincent Rajkumar, MD, and Sagar Lonial, MD, on Treating Multiple Myeloma

S. Vincent Rajkumar, MD, of the Mayo Clinic, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss key issues in treating this disease, including ...

Lymphoma

Steven P. Treon, MD, PhD, on Treating Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia

Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemi...

Advertisement

Advertisement



Advertisement